

April 8, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-3720  
Attention: Chris Edwards

**Re:**                         **LENZ Therapeutics, Inc.**  
**Registration Statement on Form S-1**  
**File No. 333-278393**

**Acceleration Request**

**Requested Date:**                 **April 10, 2024**  
**Requested Time:**                 **4:00 p.m. Eastern Time, or as soon thereafter as practicable**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, LENZ Therapeutics, Inc. (the “**Company**”) hereby requests that its Registration Statement on Form S-1 (File No. 333-278393) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Ben Capps at (858) 350-2237.

Sincerely,

LENZ THERAPEUTICS, INC.

By:           /s/ Evert Schimmelpennink  
                Evert Schimmelpennink  
                Chief Executive Officer

cc:           Daniel Chevallard, LENZ Therapeutics, Inc.  
                Dan Koeppen, Wilson Sonsini Goodrich & Rosati  
                Ben Capps, Wilson Sonsini Goodrich & Rosati